IDEAYA Biosciences begins phase 1 trial of cancer drug IDE574

April 6, 2026 6:00 AM

IDEAYA Biosciences Inc. (NASDAQ: IDYA) has enrolled the first patient in a Phase 1 dose escalation trial for IDE574, an ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

No results found